Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs Merck & Co., Inc. — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $22.66, while Merck & Co., Inc. trades at $123.52 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $98.62 | $129.52 |
52-Week Low | $21.86 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.
The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.
Merck (MRK) trades at $123.43, down 0.48% on the day, with a bullish technical signal and strong institutional buying. Recent earnings beat expectations in three of the last four quarters, with Q2 2026 results pending. The company's acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, while solid profitability metrics include a net income margin of 13.59% and ROE of 18.97% for 2025.
The outlook remains positive with a consensus price target of $137.30, implying 11% upside. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. Analysts are predominantly bullish, with 68% recommending Buy, supported by robust cash flow and strategic M&A activity to drive long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
